Literature DB >> 15627435

Effects of SEA0400, a Na+/Ca2+ exchange inhibitor, on ventricular arrhythmias in the in vivo dogs.

Yoshinobu Nagasawa1, Bing-Mei Zhu, Jianguang Chen, Kazunori Kamiya, Shigeki Miyamoto, Keitaro Hashimoto.   

Abstract

SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline), a novel and selective inhibitor of Na+/Ca2+ exchanger, was investigated for its possible antiarrhythmic effects on arrhythmias of Ca2+ overload induced by coronary ligation/reperfusion and by digitalis in the dog. SEA0400 (1.0 mg/kg) did not change the hemodynamics but slightly prolonged the QRS duration (P<0.05). Pre-ischemic administration (10 min before coronary occlusion) of SEA0400 (1.0 mg/kg) and post-ischemic administration (1 min before reperfusion) of SEA0400 (0.3, 1.0 and 3.0 mg/kg) had no effects on the incidence of ventricular fibrillation induced by coronary ligation/reperfusion. On the other hand, SEA0400 (3.0 mg/kg) decreased the arrhythmic ratio in the digitalis arrhythmias (P<0.01). However, atrioventricular block and cardiac standstill were induced in two digitalized dogs. In conclusion, SEA0400 has no significant antiarrhythmic effect on arrhythmias induced by coronary ligation/reperfusion, but has an obvious suppressing effect on tachyarrhythmias induced by digitalis in in vivo canine models.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15627435     DOI: 10.1016/j.ejphar.2004.11.011

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Triple threat: the Na+/Ca2+ exchanger in the pathophysiology of cardiac arrhythmia, ischemia and heart failure.

Authors:  Christian Pott; Lars Eckardt; Joshua I Goldhaber
Journal:  Curr Drug Targets       Date:  2011-05       Impact factor: 3.465

2.  The role of the Na+/Ca2+ exchanger, I(Na) and I(CaL) in the genesis of dofetilide-induced torsades de pointes in isolated, AV-blocked rabbit hearts.

Authors:  Attila S Farkas; Péter Makra; Norbert Csík; Szabolcs Orosz; Michael J Shattock; Ferenc Fülöp; Tamás Forster; Miklós Csanády; Julius Gy Papp; András Varró; András Farkas
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

3.  The Na+/Ca2+ exchange inhibitor SEA0400 limits intracellular Ca2+ accumulation and improves recovery of ventricular function when added to cardioplegia.

Authors:  Jeanne Egar; Ahmad Ali; Susan E Howlett; Camille Hancock Friesen; Stacy O'Blenes
Journal:  J Cardiothorac Surg       Date:  2014-01-08       Impact factor: 1.637

4.  The Effect of a Novel Highly Selective Inhibitor of the Sodium/Calcium Exchanger (NCX) on Cardiac Arrhythmias in In Vitro and In Vivo Experiments.

Authors:  Zsófia Kohajda; Nikolett Farkas-Morvay; Norbert Jost; Norbert Nagy; Amir Geramipour; András Horváth; Richárd S Varga; Tibor Hornyik; Claudia Corici; Károly Acsai; Balázs Horváth; János Prorok; Balázs Ördög; Szilvia Déri; Dániel Tóth; Jouko Levijoki; Piero Pollesello; Tuula Koskelainen; Leena Otsomaa; András Tóth; István Baczkó; István Leprán; Péter P Nánási; Julius Gy Papp; András Varró; László Virág
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

5.  New antiarrhythmic targets to control intracellular calcium handling.

Authors:  H E Driessen; V J A Bourgonje; T A B van Veen; M A Vos
Journal:  Neth Heart J       Date:  2014-05       Impact factor: 2.380

6.  The Effects of SEA0400 on Ca2+ Transient Amplitude and Proarrhythmia Depend on the Na+/Ca2+ Exchanger Expression Level in Murine Models.

Authors:  Nils Bögeholz; Jan S Schulte; Sven Kaese; B Klemens Bauer; Paul Pauls; Dirk G Dechering; Gerrit Frommeyer; Joshua I Goldhaber; Uwe Kirchhefer; Lars Eckardt; Christian Pott; Frank U Müller
Journal:  Front Pharmacol       Date:  2017-09-21       Impact factor: 5.810

Review 7.  Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias.

Authors:  Alexandra Njegic; Claire Wilson; Elizabeth J Cartwright
Journal:  Front Physiol       Date:  2020-09-04       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.